Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PSMB8 | P28062 | 2/20 | 0.50 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.47 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.47 |
| ▸ | GRB2 | P62993 | 3/20 | 0.46 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.46 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.46 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.46 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.46 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.46 |
| ▸ | HDAC10 | Q969S8 | 1/20 | 0.46 |
| ▸ | HDAC11 | Q96DB2 | 1/20 | 0.46 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.46 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.46 |
| ▸ | HDAC9 | Q9UKV0 | 1/20 | 0.46 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1105437 | 0.89 | ATM (0.53) | GRB2 | |
| SCHEMBL10042738 | 0.88 | PSMB8 (0.50) | PSMB8PSMB1PSMB2GRB2HDAC3 | |
| SCHEMBL31248331 | 0.88 | PSMB8 (0.50) | PSMB8PSMB1PSMB2GRB2HDAC3 | |
| SCHEMBL1105435 | 0.82 | KLKB1 (0.53) | — | |
| SCHEMBL13058781 | 0.82 | PSMB5 (0.43) | GRB2 | |
| SCHEMBL10042643 | 0.79 | GRB2 (0.47) | PSMB8PSMB1PSMB2GRB2 | |
| SCHEMBL10042652 | 0.79 | GRB2 (0.47) | PSMB8PSMB1PSMB2GRB2 | |
| SCHEMBL1109062 | 0.78 | CTSL (0.50) | PSMB8PSMB1PSMB2HDAC3HDAC4 | |
| SCHEMBL10042739 | 0.77 | ATM (0.53) | GRB2 | |
| SCHEMBL13058785 | 0.71 | PSMB5 (0.52) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153596-B2 | Use of SH2 STAT3/STAT1 peptidomimetics as anticancer drugs | UNIVERSITY OF SOUTH FLORIDA (US) | 2012-04-10 | — | — | US | disclosed |
| US-20090318367-A1 | Use of SH2 STAT3/STAT1 Peptidomimetics as Anticancer Drugs | UNIVERSITY OF SOUTH FLORIDA (US) | 2009-12-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090318367-A1 | Use of SH2 STAT3/STAT1 Peptidomimetics as Anticancer Drugs | STAT3, STAT1, STAT4 | PSMB8 3340/4885PSMB1 2561/4885PSMB2 2767/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.